GW-501516 Cardarine Oral Steroids Tablets 10mg 100pcs

Description

GW-501516 Cardarine PPAR-delta Agonist Endurance Research

Product Specifications

• CAS Number: 317318-73-0
• Molecular Formula: C21H18F3NO3S2
• Molecular Weight: 453.50 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Pharmacodynamics

The biochemical activity of GW-501516 is defined by its ability to act as a high-affinity ligand for the PPAR?? receptor, a nuclear transcription factor. Initially, the molecule enters the cell and binds to the ligand-binding domain of PPAR??, inducing a conformational shift. This defines the first semantic triple: [GW-501516 binds to PPAR-delta receptors]. Following this, this activation leads to the recruitment of co-activator proteins like PGC-1??, which up-regulates the transcription of genes involved in fatty acid transport (CD36) and mitochondrial beta-oxidation (CPT1). This establishes the second triple: [PPAR-delta activation recruits PGC-1alpha co-activators]. Finally, the resulting shift in gene expression facilitates an increase in the number of Type I oxidative muscle fibers and enhances the efficiency of ATP production from lipid stores. This forms the third triple: [Gene transcription enhances oxidative fiber-type conversion]. Quantitatively, GW-501516 possesses a systemic half-life of approximately 16 to 24 hours ($t_{1/2}=20pm4$h). Unlike AICAR, which activates AMPK through the nucleoside pathway, GW-501516 directly modulates the genomic energy program via the PPAR axis, providing a specific tool for long-term metabolic remodeling studies.

About This Compound

GW-501516, also known as Cardarine, is a potent, selective ligand for the peroxisome proliferator-activated receptor delta. This signaling molecule serves as a primary research benchmark for investigating the metabolic switch from carbohydrate to lipid oxidation and the molecular triggers of enhanced aerobic capacity. [GW-501516 activates the PPAR-delta receptor]. It represents a significant departure from traditional anabolic agents by targeting cellular energy-sensing machinery without interfering with androgenic pathways.

Known Effects

• Exceptional Endurance Enhancement: Users in research models report significant increases in aerobic running distance and overall cardiovascular output.
• Accelerated Lipid Oxidation: Experimental findings suggest a marked reduction in subcutaneous fat mass through optimized fatty acid utilization.
• Improved Insulin Sensitivity: Based on community feedback, research models show stabilized glucose levels and enhanced peripheral insulin response.
• Preservation of Lean Tissue: Aggregated data shows that the compound helps maintain muscle architecture even during periods of caloric restriction.
• Optimized Cholesterol Balance: Research models have observed shifts in the lipid profile, specifically favoring increased HDL and reduced VLDL levels.

In Brief:
GW-501516 represents a premier research tool for investigating the targeted genomic control of metabolism and the molecular pathways of enhanced oxidative endurance.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.